One Casualty As Takeda Refocuses Vaccine Priorities
This article was originally published in PharmAsia News
Executive Summary
Takeda has decided to end the development of a combination vaccine for polio and other disorders as part of a broader reevaluation of its vaccines pipeline to focus on outstanding global needs.